Promimic
Promimic is a Swedish medical technology company that develops and licenses nanotechnology-based surface modifications for implants. Its technology is used by implant manufacturers to improve how bone, soft tissue, and other biological structures integrate with the implant surface, with applications in orthopedics, dental implants, and other implant categories.
Fiscal year 2024 · change from previous year
Development 2021–2024
Business
Share of revenueTechnology licenses and royalty streams tied to customer implant sales.
Processing of customer implants through the U.S. subsidiary NPI.
Collaborative development work and commercialization projects with customers.
Additional implant surface and biomaterial solutions under development.
Customers
Promimic sells primarily to medical device companies that manufacture implantable products and need validated surface technologies for their own regulatory and commercial programs. The customer base includes international medtech groups and implant makers in orthopedics and dental applications, where clinical performance and regulatory acceptance are central buying criteria.
Buy surface technologies for joint, spine, trauma, and other orthopedic implants to improve clinical outcomes and differentiation.
Use Promimic's surface solutions for dental implants where faster and more reliable integration matters.
License the technology and collaborate on development, validation, and commercialization.
Buy implant processing through NPI instead of waiting for downstream royalty monetization.
Explore patientspecific implants, soft-tissue integration, and biomaterial applications.
Strategy
Promimic's strategy centers on expanding adoption of its implant surface technology through customer partnerships, clinical validation, and new license agreements. The company is also building commercial presence in the United States and broadening its offering into new implant surfaces, biomaterials, and infection-prevention applications.
The U.S. is the largest market and the main growth platform for orthopedic implants.
Longer-term royalties and adoption depend on customer integration and repeat collaborations.
New surface technologies can open additional implant categories and improve differentiation.
More customers reduce concentration and support scaling of the licensing model.
Geography
Promimic is headquartered in Mölndal, Sweden, with operations centered around GoCo Health Innovation City. Commercially, the company has its largest market in the United States, while Brazil and Europe are also important markets; reported segment operations also include Estonia, Latvia, Lithuania, Germany, and Italy.
Risks
Promimic's business depends on successful commercialization by a relatively small number of medtech customers, so delays in customer launches or regulatory approvals can directly affect future revenue. The company also faces foreign exchange exposure, especially USD, and execution risk from scaling U.S. operations while maintaining quality and regulatory compliance.
A limited number of implant partners can materially affect revenue timing and scale.
Exposure: Royalty and licensing income
Customer products must pass FDA/EMA and other regulatory reviews before commercialization.
Exposure: Customer launch timing and future royalties
Most revenue is in USD while much of the cost base is in SEK.
Exposure: Reported revenue and cash flow volatility
Scaling sales, production, and support in the U.S. requires resources and coordination.
Exposure: Growth plan execution
Adoption of new implant surface technologies can take time and depends on clinical proof.
Exposure: Pipeline conversion and market penetration
Accounting
Judgemental itemsDifferent contract types can recognize revenue at different times and under different terms.
Impact: Can shift quarterly revenue and comparability
USD net flows are hedged, so derivative valuation and hedge effectiveness affect reported results.
Impact: Affects finance income/cost and volatility
Acquired software, client databases, and other intangibles require useful-life and impairment judgments.
Impact: Can materially affect amortization and impairment charges
Growth investments and acquired assets must be tested if indicators of impairment arise.
Impact: Could lead to non-cash write-downs
Right-of-use assets and equipment are depreciated over estimated useful lives.
Impact: Affects operating expense pattern and asset base
Similar listed companies
Publicly listed companies with a comparable business focus.
Zimmer Biomet Holdings, Inc
ZBH · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Zimmer Biomet Holdings is a U.S.-based medical technology company focused on orthopedic reconstruction and related surgical care.
Bactiguard Holding
BACTI-B · Health Care
Bactiguard Holding AB is a global MedTech company based in Stockholm, Sweden, specializing in the development of biocompatible technology to prevent infections associated with medical devices.
ProMIS Neurosciences Inc.
PMN · Pharmaceutical Preparations
Establishment Labs Holdings Inc
ESTA · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Dyadic International, Inc
DYAI · Biological Products, (No Diagnostic Substances)
Dyadic International is a U.S.-based biotechnology platform company that develops microbial protein production systems for industrial, life sciences, food and…
Immunic, Inc
IMUX · Pharmaceutical Preparations
Last updated: 24/09/2026